Study on Inhibition and Mechanism of Guizhi Fuling Wan on Hepatic Fibrosis Rats
|更新时间:2024-01-04
|
Study on Inhibition and Mechanism of Guizhi Fuling Wan on Hepatic Fibrosis Rats
Chinese Journal of Experimental Traditional Medical FormulaeVol. 17, Issue 24, Pages: 171-175(2011)
作者机构:
作者简介:
基金信息:
DOI:
CLC:
Published:2011
稿件说明:
移动端阅览
LI Ji, YE Jun, XUE Dong-ying, et al. Study on Inhibition and Mechanism of Guizhi Fuling Wan on Hepatic Fibrosis Rats[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(24): 171-175.
DOI:
LI Ji, YE Jun, XUE Dong-ying, et al. Study on Inhibition and Mechanism of Guizhi Fuling Wan on Hepatic Fibrosis Rats[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(24): 171-175.DOI:
Study on Inhibition and Mechanism of Guizhi Fuling Wan on Hepatic Fibrosis Rats
Objective : Guizhi Fuling Wan which inhibited hepatic fibrosis in rats was observed and its possible mechanism of action was explored. Method : According to the random-number table
wistar rats of 60 were divided into control group of 8 (group A) and model group of 52.The control group was injected subcutaneously with normal saline by a dose of 3 mL·kg-1
model group was injected subcutaneously with 40% CCl4 to make rat liver fibrosis model by a dose of 3 mL·kg-1 for the consecutive 6 weeks. And according to the random-number table again
model group rats were divided into the model group(group B) and the treatment group which comprised low dose (group C)
middle dose (group D) and high dose (group E). Group A and group B were given normal saline by a dose of 9.0 mL·kg-1. Group C
group D and group E were given Guizhi Fuling Wan by the dose of 0.45
0.9
1.8 g·kg-1·d-1respectively
and CCl4 would be maintained subcutaneously during period of 4 weeks. After 4 weeks of treatment
general condition
body weight
liver and spleen weight and their coefficient of rats were compared in each group;rats of pathological changes in each group were determined by naked eye
light microscopy and electron microscopy
rspectively. The protein expression of α-SMA
TGF-β1
CTGF
Co-Ⅰ and Co-Ⅲ was detected by using immunohistochemical stains in each group. The mRNA genetic expression of α-SMA
TGF-β1
CTGF
Co-Ⅰ and Co-Ⅲ was detected by using Real-time quantitative PCR in each group. Result : Immunohistochemical stains and real-time quantitative PCR: In model group
protein and mRNA genetic expression of α-SMA
TGF-β1
CTGF
Co-Ⅰ and Co-Ⅲ was significantly increased in liver tissue (P<0.01
vs control group).All the treatment group could bring down protein and mRNA genetic expression of α-SMA
TGF-β1
CTGF
Co-Ⅰ and Co-Ⅲ in liver tissue of rats. Among the treatment group
group D and group E decreased mRNA genetic expression of α-SMA
Co-Ⅰ and Co-Ⅲ significantly (P<0.05 or P<0.01 vs model group)
and Group Elessened protein expression of TGF-β1
CTGF obviously(P<0.05 vs model group). Among the treatment group
group D and group E cut down mRNA genetic expression of α-SMA
TGF-β1
CTGF significantly(P<0.01 vs model group)
and group E of all the treatment group reduced evidently genetic mRNA expression of Co-Ⅰ and Co-Ⅲ (P <0.01 vs model group). Conclusion : Guizhi Fuling Wan suspension can effectively inhibit liver α-SMA